Global U.S. Influenza Vaccines Market Is Expanding Owing To Growing Government Initiatives to Support Influenza Vaccination And Increasing Vaccine Production Facilities
U.S. Influenza Vaccines Market |
Overview:
Influenza
vaccines are used to protect people at high risk for serious flu complications,
including children, pregnant women and those with chronic health conditions.
They help prevent the illness, reduce flu-related hospitalizations and save
lives. Vaccines contain active flu viruses that have been modified or weakened.
A single shot of an inactivated influenza vaccine (IIV) is generally effective
for protecting against seasonal flu. Influenza vaccines can be given as an
injection or as a nasal spray. They are also available as a trivalent or
quadrivalent vaccine that contains 2 different types of flu viruses. The
influenza vaccine is safe and has a good immune response in most healthy
people. Some may experience mild side effects such as fever and sore throat.
Symptoms usually clear up within a few days.
Market Dynamics:
Rising investments are estimated to
augment growth of the global
U.S. influenza vaccines market during the forecast period. For instance, USD 679 million
were invested by Sanofi in a new vaccine manufacturing facility in Toronto in
March 2021. This investment will help in boosting their supply chains in Europe
and China. Moreover, rising cost of R&D and the extended timeline for
introducing a new vaccine are anticipated to restrain growth of the global U.S. influenza vaccines
market during the forecast period.
Impact
of COVID-19:
The pandemic was first reported in
China and it led to shutting down the entire country. The COVID-19 virus
affected the respiratory system and was being transmitted by coming in direct
contact with an infected individual. To avoid any further transmission of the
virus several nations imposed strict social distancing rules across the world.
The pandemic resulted in increasing the demand for influenza vaccines, as the
number of cases increased. There was no particular vaccine or drugs for
treating COVID-19, so doctors were relying on such vaccines. This had a
positive impact on the growth of the global
U.S. influenza vaccines market.
Key Takeaways:
The
global U.S. influenza vaccines
market is
estimated to witness robust growth, exhibiting CAGR of 16.3 % during the
forecast period, due to rising research and developmental activities by key
players. For instance, Vaxess Technologies Inc.,
declared the launch of a phase I trial for H1 influenza vaccine which will be
delivered by Vaxess’s MIMIX patch, in August 2022.
North America is anticipated to witness
robust growth in the global
U.S. influenza vaccines market during the forecast period, due to
rising product launches and increasing vaccine
production facilities in the region.
Key players active in the global U.S. influenza vaccines
market are EMERGEX VACCINES, GSK plc, OSIVAX, AstraZeneca, Viatris Inc.,
SINOVAC, Merck & Co., Inc., Pfizer Inc, EMERGENT, Vaxess Technologies Inc,
and CSL Limited.
Comments
Post a Comment